EBOS GROUP LIMITED — AGM Information 2016

Oct 18, 2016

==> picture [780 x 15] intentionally omitted <==

EBOS Group Limited

94[th] Annual Meeting

[19 October 2016 ]

==> picture [780 x 15] intentionally omitted <==

Important Information

The information in this presentation was prepared by EBOS Group Ltd with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or reliability of the information. In addition, neither the EBOS Group nor any of its subsidiaries, directors, employees, shareholders nor any other person shall have liability whatsoever to any person for any loss (including, without limitation, arising from any fault or negligence) arising from this presentation or any information supplied in connection with it.

This presentation may contain forward-looking statements and projections. These reflect EBOS’s current expectations, based on what it thinks are reasonable assumptions. EBOS gives no warranty or representation as to its future financial performance or any future matter. Except as required by law or NZX or ASX listing rules, EBOS is not obliged to update this presentation after its release, even if things change materially. This presentation does not constitute financial advice. Further, this presentation is not and should not be construed as an offer to sell or a solicitation of an offer to buy EBOS Group securities and may not be relied upon in connection with any purchase of EBOS Group securities.

This presentation contains a number of non-GAAP financial measures, including Gross Operating Revenue, EBIT, EBITA, EBITDA, Free Cash Flow, Net Debt and Return on Capital Employed. Because they are not defined by GAAP or IFRS, EBOS’s calculation of these measures may differ from similarly titled measures presented by other companies and they should not be considered in isolation from, or construed as an alternative to, other financial measures determined in accordance with GAAP. Although EBOS believes they provide useful information in measuring the financial performance and condition of EBOS's business, readers are cautioned not to place undue reliance on these non-GAAP financial measures.

All currency amounts are in New Zealand dollars unless stated otherwise.

==> picture [114 x 43] intentionally omitted <==

2

==> picture [390 x 231] intentionally omitted <==

==> picture [392 x 230] intentionally omitted <==

==> picture [390 x 251] intentionally omitted <==

2016 Annual Meeting 1 Chairman – Mr Mark Waller

3

==> picture [780 x 15] intentionally omitted <==

Agenda

• Welcome

• Introducing members of the Board

• Presentations

• Mark Waller, Chairman

• Patrick Davies, Chief Executive Officer

• Business of meeting

• Conclusion

==> picture [114 x 43] intentionally omitted <==

4

==> picture [780 x 15] intentionally omitted <==

Board of Directors

==> picture [82 x 122] intentionally omitted <==

Mark Waller

Independent Chairman of Directors

Appointed 1987 Appointed Chairman 2015

==> picture [82 x 122] intentionally omitted <==

Elizabeth Coutts Independent Director Joined 2003

==> picture [82 x 122] intentionally omitted <==

==> picture [82 x 122] intentionally omitted <==

==> picture [82 x 122] intentionally omitted <==

Peter Kraus Stuart McGregor Sarah Ottrey Non-executive Director Non-executive Director Independent Director Joined 1990 Joined 2013 Joined 2006

==> picture [81 x 122] intentionally omitted <==

==> picture [82 x 122] intentionally omitted <==

Barry Wallace Peter Williams Non-executive Director Non-executive Director Joined 2001 Joined 2013

==> picture [114 x 43] intentionally omitted <==

5

==> picture [780 x 15] intentionally omitted <==

Record Revenue and Profit Performance for FY16

Total Revenue $  Up 17.0% (+16.5% Constant FX)

$  7.1b Up 17.0% (+16.5% Constant FX) Total EBITDA  $ 225.5m

Return on Capital Employed  16.3% Up 260bps

Earnings per share  84.0c

Up 14.6% (+14.0% Constant FX)

Up 18.7% (+18.2% Constant FX)

Total NPAT  $ 127.0m Up 19.9% (+19.3% Constant FX)

Final Dividend per share  32.5c

Up 30.0%

==> picture [114 x 43] intentionally omitted <==

6

==> picture [780 x 15] intentionally omitted <==

Financial Trends

5 Year Revenue Trend (NZ$m) 5 Year EBITDA Trend (NZ$m)

==> picture [277 x 181] intentionally omitted <==

----- Start of picture text -----

2016 7,101
2015 6,068
2014 5,757
2013 1,822
2012 1,427
----- End of picture text -----

==> picture [281 x 181] intentionally omitted <==

----- Start of picture text -----

2016 225.5
2015 196.7
2014 175.4
2013 57.0
2012 45.1
----- End of picture text -----

Revenue Split – FY16

EBITDA Split – FY16

==> picture [620 x 179] intentionally omitted <==

----- Start of picture text -----

New New
Zealand 21% Zealand 20%
79% Australia 80% Australia
----- End of picture text -----

7

==> picture [780 x 15] intentionally omitted <==

Business Segment overview

==> picture [644 x 438] intentionally omitted <==

----- Start of picture text -----

ANIMAL
CARE 16%
Animal Care
16%
Consumer
Products 6%
Contract
Pharmacy
Logistics
49%
9%
(Wholesale
and Retail)
HEALTHCARE
Institutional
Healthcare 84%
20%
----- End of picture text -----

==> picture [114 x 43] intentionally omitted <==

Data based on Gross Operating Revenue FY16

8

==> picture [780 x 459] intentionally omitted <==

2 2016 Annual Meeting CEO – Mr Patrick Davies

A-Frame automatic picking system, Symbion Keysborough facility, 9 Melbourne, Australia

==> picture [780 x 15] intentionally omitted <==

EBOS Approach

==> picture [61 x 63] intentionally omitted <==

Our Healthcare and Animal Care strategic focus is centred on

==> picture [63 x 65] intentionally omitted <==

Investing for Growth

Leading Market Positions

Disciplined Capital Management

Two types of investments:

• External acquisitions – we have a strong history of deal execution.

==> picture [76 x 26] intentionally omitted <==

==> picture [50 x 27] intentionally omitted <==

==> picture [68 x 26] intentionally omitted <==

• Internal Capex – investment to lift productivity, manage cost and deliver better customer service.

We aim to have positions of scale in the markets we operate in and maximise opportunities across our wide range of business segments wherever possible.

• Cash generation to drive scope for further investment which allows for dividends paid in the range of 60-70% of Net Profit After Tax.

• Acquisitions focus on improving the Group’s return on capital employed.

We focus on delivering profitable growth and superior returns

==> picture [114 x 43] intentionally omitted <==

10

==> picture [780 x 15] intentionally omitted <==

FY16 Highlights

Investments of $108.4m made in FY16

• Acquisition of Red Seal (November 2015)

==> picture [50 x 18] intentionally omitted <==

==> picture [38 x 21] intentionally omitted <==

• Acquisition of Zest (October 2015)

==> picture [30 x 30] intentionally omitted <==

• Onelink’s NSW Health contract commenced

==> picture [36 x 27] intentionally omitted <==

• Initial investment made in a new distribution centre in Brisbane, Queensland

==> picture [32 x 31] intentionally omitted <==

• BlackHawk like-for-like annual sales growth of 55%

• Post balance date announcement to merge Chemmart with Terry White Group Limited to create one of Australia’s largest retail pharmacy networks.

==> picture [33 x 33] intentionally omitted <==

==> picture [114 x 43] intentionally omitted <==

11

==> picture [780 x 15] intentionally omitted <==

Corporate video

• The corporate video that will be shown at the Annual Meeting can be viewed on the EBOS Group website at www.ebosgroup.com

==> picture [114 x 43] intentionally omitted <==

12

==> picture [780 x 15] intentionally omitted <==

FY16 Divisional Performance

					Constant FX
NZ$m	FY16	FY15	Var		Var
Healthcare segment
Revenue	6,686.4	5,692.9	17.5%		16.9%
EBITDA	195.0	170.2	14.6%		14.2%
EBIT	174.1	149.7	16.3%		15.9%
EBITDA%	2.92%	2.99%	-7pts		-7pts

• Healthcare Revenue increased $993.5m or 16.9% due to:

• new Hepatitis C drug sales in Australia of $465m, albeit at lower gross profit margins

• Strong OTC product category sales across both countries

• New business won, including a contribution from Red Seal

• Healthcare EBITDA increase of $24.8m or 14.2% driven by the significant sales growth

NZ$m	FY16 FY15 Var 415.0 375.2 10.6% 42.3 37.1 14.0% 38.6 33.5 15.3% 10.19% 9.89% 30pts	Constant FX Var
Animal Care segment Revenue EBITDA EBIT EBITDA%		10.0% 13.0% 14.3% 28pts

• Animal Care Revenue increased $39.8m or 10.0% primarily from growth of branded products (including BlackHawk, Vitapet) and wholesale operations (Lyppard)

• Animal Care EBITDA increase of $5.2m or 13.0% attributable to:

• revenue growth;

• full financial year of BlackHawk contribution (acquired 31 October 2014); and

• higher contribution from our 50% share in Animates.

==> picture [114 x 43] intentionally omitted <==

13

==> picture [780 x 15] intentionally omitted <==

FY17 Trading Update

• We have made a positive start to the first quarter of FY17, notwithstanding the higher NZD:AUD exchange rate which has been evident. On the basis of our current trading performance we expect constant currency, underlying net profit after tax for the 2017 financial year to grow by 7%-10% on the prior year.

==> picture [114 x 43] intentionally omitted <==

14

==> picture [780 x 15] intentionally omitted <==

==> picture [136 x 114] intentionally omitted <==

==> picture [178 x 112] intentionally omitted <==

==> picture [137 x 114] intentionally omitted <==

==> picture [66 x 83] intentionally omitted <==

==> picture [376 x 188] intentionally omitted <==

==> picture [117 x 206] intentionally omitted <==

==> picture [168 x 174] intentionally omitted <==

==> picture [290 x 243] intentionally omitted <==

3 2016 Annual Meeting Business of the Meeting

Selection of our branded products from Red Seal, Faulding, Vitapet and BlackHawk 15

==> picture [780 x 15] intentionally omitted <==

Item 1

Annual Report and Financial Statements

• To consider and receive the annual report and the financial statements for the year ended 30 June 2016 and the audit report thereon.

==> picture [114 x 43] intentionally omitted <==

16

==> picture [780 x 15] intentionally omitted <==

Item 2

Director re-election – Elizabeth Coutts

To consider the re-election of Elizabeth Coutts as a Director of the Company. Elizabeth Coutts retires by rotation and being eligible, offers herself for reelection.

Elizabeth Coutts ONZM, BMS, CA Independent Director

==> picture [154 x 156] intentionally omitted <==

Elizabeth Coutts was appointed to the EBOS Group Limited Board in July 2003. She is a member of the Audit and Risk Committee, the Remuneration Committee and the Nomination Committee. She is Chair of Ports of Auckland Ltd, Urwin & Co Limited and Oceania Healthcare Ltd, and Director of Yellow Pages group of companies, Sanford Limited, Skellerup Holdings Limited and Tennis Auckland Region Incorporated and Member, Marsh New Zealand Advisory Board. She is Vice President of the Institute of Directors Inc.

Elizabeth is a former Chairman of Meritec Group, Industrial Research, and Life Pharmacy Limited, former director of Air New Zealand Limited and the Health Funding Authority, former Deputy Chairman of Public Trust, former board member of Sport NZ, former member of the Pharmaceutical Management Agency (Pharmac), former Commissioner for both the Commerce and Earthquake Commissions, former external monetary policy adviser to the Governor of the Reserve Bank of New Zealand and former Chief Executive of the Caxton Group of Companies.

==> picture [114 x 43] intentionally omitted <==

17

==> picture [780 x 15] intentionally omitted <==

Item 3

Director re-election – Peter Williams

To consider the re-election of Peter Williams as a Director of the Company. Peter Williams retires by rotation and being eligible, offers himself for reelection.

Peter Williams

Non-executive Director

==> picture [143 x 142] intentionally omitted <==

[Peter Williams was appointed to the EBOS Group Limited Board in July 2013. He is a member of ] the Nomination Committee. Peter has been an executive of The Zuellig Group since 2000. Peter is a director of Pharma Industries Limited and Cambert, a company marketing health and personal care products in South East Asia. Peter is a former director of Interpharma Investments Limited.

==> picture [114 x 43] intentionally omitted <==

18

==> picture [780 x 15] intentionally omitted <==

Item 4

Director re-election – Mark Waller

To consider the re-election of Mark Waller as a Director of the Company. Mark Waller retires by rotation and being eligible, offers himself for reelection.

Mark Waller

BCOM, FACA, FNZIM Independent Chairman of Directors

==> picture [148 x 139] intentionally omitted <==

Mark Waller was appointed as Chairman of the Board in October 2015 and was formerly the Chief Executive and Managing Director of EBOS Group Limited from 1987 to 30 June 2014. He is a member of the Audit and Risk Committee and Chairman of the Remuneration Committee and the Nomination Committee. He is also a director of all the EBOS Group Limited subsidiaries, as well as being a director of Scott Technology Limited and HTS-110 Limited (alternate director). He was the recipient of the Leadership Award at the INFINZ Industry Awards in May 2014 and the Chief Executive of the Year Award at the Deloitte 200 Awards in 2011.

==> picture [114 x 43] intentionally omitted <==

19

==> picture [780 x 15] intentionally omitted <==

Item 5

Auditor fees and expenses

• That the directors be authorised to fix the fees and expenses of Deloitte as the auditor of the Company.

==> picture [114 x 43] intentionally omitted <==

20

==> picture [780 x 15] intentionally omitted <==

2016 Annual Meeting

Thank you for attending Please join us for refreshments

www.ebosgroup.com